BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» TCM-focused Baiyunshan seeking to raise $1.6B to boost R&D operations
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
TCM-focused Baiyunshan seeking to raise $1.6B to boost R&D operations
Jan. 21, 2015
By
Cornelia Zou
No Comments
HONG KONG – Diversified traditional Chinese medicine (TCM) maker Guangzhou Baiyunshan Pharmaceutical Holdings (HK:0874, SH:600332) plans to raise as much as $1.6 billion through a private sale of new shares to be traded in Mainland China.
BioWorld Asia